Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AAVCAGsCD59 · 1 trial · 1 indication
Measure intraocular inflammation, ocular changes and systemic side effects following a single intraocular injection of AAVCAGsCD59
| Arm | Type | Description |
|---|---|---|
| Low Dose | EXPERIMENTAL | AAVCAGsCD59 |
| Mid Dose | EXPERIMENTAL | AAVCAGsCD59 |
| High Dose | EXPERIMENTAL | AAVCAGsCD59 |
| Name | Type | Description |
|---|---|---|
| AAVCAGsCD59 | BIOLOGICAL | AAVCAGsCD59 is administered as a single intravitreal injection in an office setting |
Inclusion Criteria: * Men or women 50 years of age or older * Advanced dry AMD with GA in the study eye * BCVA Snellen equivalent of 20/80 or worse in the study eye using ETDRS charts at a starting distance of 4m after the first 3 patients are enrolled and demonstrate favorable safety data * Total ...
AAVCAGsCD59 is an investigational gene therapy being studied for the treatment of advanced dry age-related macular degeneration (AMD). It is administered to patients aged 50 years and older. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AAVCAGsCD59 is a gene therapy designed to deliver the CD59 gene, which encodes a protein that inhibits the complement system, a part of the immune response implicated in the progression of dry age-related macular degeneration. By expressing CD59, the therapy aims to protect retinal cells from complement-mediated damage.
AAVCAGsCD59 is being developed by Johnson & Johnson (NYSE: JNJ). The company is conducting clinical research on this gene therapy for the treatment of advanced dry age-related macular degeneration.
AAVCAGsCD59 is in Phase 1 clinical development. A single Phase 1 trial has been completed, involving 17 participants with dry age-related macular degeneration. The drug remains investigational and is not yet approved for commercial use.
AAVCAGsCD59 has one completed clinical trial registered as NCT03144999, titled 'Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59.' This Phase 1 study enrolled 17 participants in the United States and evaluated the therapy in patients with dry age-related macular degeneration.
Yes, AAVCAGsCD59 is the drug name used in clinical trial registrations and research. No alternative names have been reported for this investigational gene therapy.